ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK
Latest Information Update: 14 Aug 2024
At a glance
- Drugs Defactinib (Primary) ; Carboplatin; Paclitaxel
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms ROCKIF Trial
- 12 Aug 2024 Planned End Date changed from 1 Oct 2024 to 1 Apr 2026.
- 12 Aug 2024 Planned primary completion date changed from 1 Sep 2023 to 1 Apr 2025.
- 10 Oct 2018 Planned End Date changed from 1 Oct 2023 to 1 Oct 2024.